Comparison of existing prognostication models in MDS
| Model . | Variables . | C index . | Reference . |
|---|---|---|---|
| International Prognostic Scoring System (IPSS)2 | Karyotype BM blasts % Number of cytopenias | 0.65 | 2 |
| Revised International Prognostic Scoring System (IPSS-R)3 | Karyotype BM blasts % Degree of cytopenias | 0.67 | 3 |
| MD Anderson Cancer Center (MDACC)55 | Karyotype BM blasts % Degree of cytopenias Age Performance status Prior transfusion | 0.65 | 49 |
| World Health Organization-based Prognostic Scoring System (WPSS)56 | Karyotype WHO category Transfusion requirement | 0.65 | 50 |
| Genoclinical model according to Haferlach et al8 | Gender Age Degree of cytopenias (PLT, Hb) BM blasts % Karyotype ASXL1, CBL, ETV6, EZH2, KRAS, LAMB4, NCOR2, NF1, NPM1, NRAS, PRPF8, RUNX1, TET2, TP53 | NA | 8 |
| Genoclinical model according to Nazha et al10 | Karyotype BM blasts % Degree of cytopenias Age WHO category Disease ontogeny (secondary vs de novo) TP53, EZH2, and SF3B1 | 0.71 | 10 |
| Genoclinical model according to Bersanelli et al15 | 63 clinical and molecular variables | 0.75 | 14 |
| Model . | Variables . | C index . | Reference . |
|---|---|---|---|
| International Prognostic Scoring System (IPSS)2 | Karyotype BM blasts % Number of cytopenias | 0.65 | 2 |
| Revised International Prognostic Scoring System (IPSS-R)3 | Karyotype BM blasts % Degree of cytopenias | 0.67 | 3 |
| MD Anderson Cancer Center (MDACC)55 | Karyotype BM blasts % Degree of cytopenias Age Performance status Prior transfusion | 0.65 | 49 |
| World Health Organization-based Prognostic Scoring System (WPSS)56 | Karyotype WHO category Transfusion requirement | 0.65 | 50 |
| Genoclinical model according to Haferlach et al8 | Gender Age Degree of cytopenias (PLT, Hb) BM blasts % Karyotype ASXL1, CBL, ETV6, EZH2, KRAS, LAMB4, NCOR2, NF1, NPM1, NRAS, PRPF8, RUNX1, TET2, TP53 | NA | 8 |
| Genoclinical model according to Nazha et al10 | Karyotype BM blasts % Degree of cytopenias Age WHO category Disease ontogeny (secondary vs de novo) TP53, EZH2, and SF3B1 | 0.71 | 10 |
| Genoclinical model according to Bersanelli et al15 | 63 clinical and molecular variables | 0.75 | 14 |
PLT, platelets; NA, not available.